Detalles de la búsqueda
1.
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Diabetes Obes Metab
; 25(2): 491-500, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36251282
2.
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.
Diabetes Obes Metab
; 25(3): 639-648, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36342041
3.
The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data.
Diabetes Obes Metab
; 23(7): 1604-1613, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33729661
4.
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Diabetes Obes Metab
; 21(3): 611-621, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30362224
5.
The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
Diabetes Obes Metab
; 20(10): 2371-2378, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29797389
6.
The Short-Term Cost-Effectiveness of a Fixed-Ratio Combination of Insulin Degludec and Aspart: A Cost of Control Analysis in Australia and India.
Value Health Reg Issues
; 41: 108-113, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38320441
7.
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
BMJ Open
; 13(9): e070473, 2023 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775297
8.
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
Diabetes Ther
; 14(6): 1005-1021, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37120480
9.
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
Eur J Health Econ
; 24(6): 895-907, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36114904
10.
Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands.
Clinicoecon Outcomes Res
; 15: 87-96, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36778040
11.
Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
J Med Econ
; 26(1): 1019-1031, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37525970
12.
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Adv Ther
; 39(7): 3180-3198, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35553372
13.
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Diabetol Metab Syndr
; 14(1): 32, 2022 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35164855
14.
The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Diabetes Res Clin Pract
; 175: 108759, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33744377
15.
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Adv Ther
; 37(5): 2427-2441, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32306244
16.
Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Adv Ther
; 37(10): 4427-4445, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862365
17.
Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
J Med Econ
; 23(2): 193-203, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31613199
18.
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
Diabetes Ther
; 11(2): 509-521, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31925724
19.
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Diabetes Ther
; 11(1): 259-277, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31833042
20.
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
J Med Econ
; 23(11): 1311-1320, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32746676